Oxitec Is A British Biotechnology Company Founded In 2002, Specializing In The Development Of Genetically Modified Insects To Enhance Public Health And Food Security. The Company Focuses On Controlling Insect Populations That Spread Diseases Or Damage Crops Through Its Innovative Technology. By Releasing Genetically Engineered Male Insects, Oxitec Aims To Reduce Wild Populations, As Their Female Offspring Do Not Survive To Maturity. This Method Is Designed To Be More Effective And Environmentally Friendly Compared To Traditional Chemical Insecticides. Initially Targeting The Pink Bollworm, Oxitec Has Expanded Its Efforts To Include Genetically Modified Aedes Aegypti Mosquitoes To Combat Diseases Like Dengue And Chikungunya. The Company Is Also Working On Technologies To Suppress Malaria-spreading Mosquitoes In Collaboration With The Bill & Melinda Gates Foundation. With Headquarters Near Oxford University And Facilities In Brazil And The USA, Oxitec Promotes Safety, Scientific Integrity, And Transparency, Supported By Over 100 Peer-reviewed Scientific Papers. Their Mission Is To Make Insect Control Technologies Accessible To Various Stakeholders, Aiming To Eliminate Vector-borne Diseases And Sustainably Manage Agricultural Pests Globally.